What is the average dose of Wegovy for weight loss — and how do you get there?

Why the 2.4 mg figure needs a bit of context

When people ask about the average Wegovy dose, they usually want to know whether 2.4 mg is where they will end up and what that looks like week to week. You can read more about what the average dose of Wegovy looks like in practice, but the short answer is: for most people, 2.4 mg is the destination, but the journey takes about four to five months to get there.

The UK licensed pathway starts at 0.25 mg, a dose too low to drive significant weight loss on its own. Its job is to let your body adjust to the medicine. From there, the prescriber moves you up roughly every four weeks: 0.25 mg, then 0.5 mg, then 1 mg, then 1.7 mg, and finally 2.4 mg. That gives most people around 16 to 20 weeks before they are on the standard maintenance dose. The NHS semaglutide guidance describes this schedule clearly, and it reflects what was used in the clinical trials.

The word "average" matters here. Some people stay longer at an intermediate dose if they are finding tolerability difficult. Nausea, indigestion and loose stools are common early on, particularly after each step up. A prescriber might pause the titration at, say, 1 mg rather than push on prematurely. That clinical judgement is exactly what makes a supervised pathway different from simply following a number. You can get a sense of what to expect at earlier stages (including what weight loss typically looks like at the starter dose) though meaningful results generally build as the dose rises.

The decision point: 2.4 mg or the new 7.2 mg?

Since April 2026, there is a second decision on the table for some people. The MHRA approved a dedicated single-dose 7.2 mg Wegovy pen on 14 April 2026, giving prescribers the option of a higher maintenance dose for adults with a BMI of 30 or above. If you are wondering about what the highest dose of Wegovy for weight loss involves, trials at this level reported average weight loss of around 20.7% over 72 weeks, notably closer to what tirzepatide (Mounjaro) achieves at its highest dose.

The 7.2 mg route still begins at 0.25 mg and steps up in the same four-weekly pattern; the new pen is simply the upper ceiling rather than a shortcut. Whether you are a candidate for the higher dose is something a prescriber weighs based on your response so far, your tolerability and your overall health picture. For a fuller breakdown of each available strength, the complete Wegovy dose guide covers the schedule in detail.

A quick habit worth building: before each step-up, check the date of your last injection and the dose printed on the pen. It takes under a minute and avoids the common slip of staying on a lower strength by mistake when a new pen arrives in a different box.

What the evidence says, and what it does not guarantee

The STEP 1 trial found an average weight loss of roughly 15% over 68 weeks at 2.4 mg, in adults without diabetes who also made lifestyle changes. That is a headline figure. In practice, responses vary: some people lose more, some less, and weight loss tends to slow or plateau well before the end of treatment. This is why the NICE recommendation for semaglutide (TA875) includes a review point, if less than 5% of body weight has gone after six months at the highest tolerated dose, continuing is reassessed.

The evidence also makes clear that lifestyle changes alongside treatment matter. Appetite falls significantly on Wegovy, which makes eating less easier, but adequate protein, hydration and movement all influence how well the body preserves muscle mass while losing fat. A prescriber or dietitian is the right person to give you a personalised steer on that; generalisations only go so far.

It is also worth knowing that NICE recommends Wegovy only for a maximum of two years, and only within a specialist weight management service. The private route, through a regulated pharmacy like ours, follows the same clinical standards, prescriber-reviewed, properly monitored, and not available simply because you ask. If you are weighing up what treatment might cost privately, our Wegovy pricing page explains what a legitimate prescription includes.

Who reaches 2.4 mg, and when does it make sense to ask?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI from 27 upwards where at least one weight-related health condition is present. Conditions that count include high blood pressure, high cholesterol, type 2 diabetes and obstructive sleep apnoea, among others. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Children and young people under 18 are not within the licensed indication, and Wegovy is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive.

None of this means 2.4 mg is the automatic outcome if you meet those criteria. A prescriber looks at the full picture, other medicines you take, your history, your goals. The titration schedule then unfolds at the pace that suits your physiology, not a fixed calendar. Our Wegovy overview page sets out the broader picture of how the medicine works, and our clinical team reviews every consultation personally before anything is prescribed. If you would like to understand whether Wegovy could be right for you, a free consultation is the place to start.

Check your eligibility with a free consultation